Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Liquidia Corporation - Common Stock (NQ:LQDA)

14.21 -0.31 (-2.13%)
Streaming Delayed Price Updated: 12:47 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
7 Analysts Have This To Say About Liquidia
Via Benzinga
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
From Liquidia Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Liquidia Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
The Analyst Landscape: 5 Takes On Liquidia
Via Benzinga
Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Unveiling 6 Analyst Insights On Liquidia
Via Benzinga
Recap: iShares $ Corp Bond UCITS ETF Q4 Earnings
Via Benzinga
Topics ETFs
Liquidia Earnings Preview
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
LQDA Stock Earnings: Liquidia Misses EPS, Misses Revenue for Q1 2024
LQDA stock results show that Liquidia missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
From Liquidia Corporation
Via GlobeNewswire
Jim Cramer: You're 'Dice Rolling' With This Biopharma Stock, But Vista Energy Is 'A Good Situation'
"Mad Money Lightning Round," Jim Cramer recommended buying Cloudflare. "I would buy it slowly because we've got big selling going on in AI stock Meta," he added. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
From Liquidia Corporation
Via GlobeNewswire
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Build-A-Bear Workshop Reports Upbeat Earnings, Joins VAALCO Energy, Dick's Sporting Goods And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
From Liquidia Corporation
Via GlobeNewswire
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings
Legal battle unfolds as United Therapeutics challenges FDA's handling of Liquidia's drug approval process. Explore the implications on PH-ILD, potential 30-month stay, and recent financial... 
Via Benzinga
Exposures Product Safety
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
From Liquidia Corporation
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.